Hamilton Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.06M | Sell |
4,876
-916
| -16% | -$203K | 0.05% | 41 |
|
|
2025
Q4 | $1.32M | Buy |
+5,792
| New | +$1.32M | 0.07% | 33 |
|
|
2025
Q2 | $553K | Sell |
2,980
-5,495
| -65% | -$1.02M | 0.03% | 57 |
|
|
2025
Q1 | $1.78M | Sell |
8,475
-1,209
| -12% | -$235K | 0.11% | 23 |
|
|
2024
Q4 | $1.72M | Sell |
9,684
-3,606
| -27% | -$663K | 0.13% | 24 |
|
|
2024
Q3 | $2.71M | Buy |
13,290
+253
| +2% | +$47.2K | 0.2% | 17 |
|
|
2024
Q2 | $2.24M | Sell |
13,037
-447
| -3% | -$74K | 0.17% | 15 |
|
|
2024
Q1 | $2.46M | Buy |
13,484
+577
| +4% | +$99.4K | 0.18% | 15 |
|
|
2023
Q4 | $2M | Buy |
12,907
+5,748
| +80% | +$838K | 0.16% | 16 |
|
|
2023
Q3 | $1.07M | Sell |
7,159
-133
| -2% | -$19.5K | 0.08% | 25 |
|
|
2023
Q2 | $983K | Buy |
7,292
+645
| +10% | +$94.6K | 0.07% | 29 |
|
|
2023
Q1 | $1.06M | Sell |
6,647
-1,387
| -17% | -$212K | 0.07% | 25 |
|
|
2022
Q4 | $1.3M | Buy |
8,034
+1,274
| +19% | +$195K | 0.08% | 26 |
|
|
2022
Q3 | $907K | Buy |
6,760
+138
| +2% | +$19.8K | 0.06% | 27 |
|
|
2022
Q2 | $1.01M | Buy |
6,622
+117
| +2% | +$17.9K | 0.06% | 25 |
|
|
2022
Q1 | $1.05M | Buy |
6,505
+443
| +7% | +$64.4K | 0.07% | 25 |
|
|
2021
Q4 | $821K | Buy |
6,062
+264
| +5% | +$31.2K | 0.06% | 44 |
|
|
2021
Q3 | $625K | Sell |
5,798
-90
| -2% | -$10.3K | 0.05% | 32 |
|
|
2021
Q2 | $663K | Sell |
5,888
-105
| -2% | -$11.8K | 0.06% | 27 |
|
|
2021
Q1 | $649K | Sell |
5,993
-18
| -0.3% | -$1.93K | 0.07% | 22 |
|
|
2020
Q4 | $644K | Buy |
6,011
+288
| +5% | +$27.7K | 0.11% | 18 |
|
|
2020
Q3 | $501K | Sell |
5,723
-495
| -8% | -$46.6K | 0.19% | 19 |
|
|
2020
Q2 | $610K | Buy |
6,218
+573
| +10% | +$50.5K | 0.23% | 16 |
|
|
2020
Q1 | $430K | Buy |
5,645
+20
| +0.4% | +$1.7K | 0.16% | 20 |
|
|
2019
Q4 | $498K | Hold |
5,625
| – | – | 0.21% | 22 |
|
|
2019
Q3 | $426K | Sell |
5,625
-308,175
| -98% | -$21.1M | 0.21% | 15 |
|
|
2019
Q2 | $22.8M | Buy |
313,800
+306,802
| +4,384% | +$24.1M | 7.88% | 5 |
|
|
2019
Q1 | $564K | Buy |
6,998
+100
| +1% | +$8.18K | 0.25% | 15 |
|
|
2018
Q4 | $551K | Sell |
6,898
-495
| -7% | -$43.5K | 0.25% | 14 |
|
|
2018
Q3 | $699K | Buy |
7,393
+756
| +11% | +$71.7K | 0.26% | 13 |
|
|
2018
Q2 | $615K | Hold |
6,637
| – | – | 0.23% | 12 |
|
|
2018
Q1 | $628K | Hold |
6,637
| – | – | 0.23% | 13 |
|
|
2017
Q4 | $642K | Buy |
+6,637
| New | +$626K | 0.24% | 12 |
|
Other funds holding ABBV
VCM
VPM
Hamilton Capital's ABBV Position: Q1 2026 in Review
Hamilton Capital reduced its AbbVie (ABBV) stake by 16% in Q1 2026, selling an estimated $203K and leaving 4,876 shares worth $1.06M. The position accounts for 0.05% of the portfolio, ranked #41.
Hamilton Capital first reported a position in ABBV in Q4 2017 and has held it in 33 quarters since. The position peaked at $22.8M in Q2 2019. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Hamilton Capital held 4,876 shares of AbbVie worth $1.06M as of Q1 2026.
- Hamilton Capital sold 916 AbbVie shares in Q1 2026, an estimated $203K.
- AbbVie made up 0.05% of Hamilton Capital's portfolio in Q1 2026, its #41 holding.
- Hamilton Capital first reported a position in AbbVie in Q4 2017 and has held it in 33 quarters since.
- Hamilton Capital's AbbVie position peaked at $22.8M in Q2 2019.
- 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Hamilton Capital's 13F filing for Q1 2026, filed 15 May 2026.